Every S-1 that Aspire-Lakewood Holdings, Inc. (ASBP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow ASBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASBP filings page.
Aspire Biopharma Holdings, Inc. is registering up to 159,090,906 shares of common stock for resale by existing investors, issuable upon conversion of its Series A Convertible Preferred Stock. These selling shareholders, not the company, will receive any proceeds from share sales.
The Preferred Stock supports up to $20 million of financing, with a first tranche of $11 million already funded on February 6, 2026 and a potential second tranche of up to $10 million contingent on conditions including effectiveness of this registration. The preferred converts at a variable price with a $0.264 per-share floor and a 4.99%–9.99% beneficial ownership cap, limiting how much common stock any holder can own after conversion.
Aspire is an early-stage biopharmaceutical and supplements company focused on patent-pending sublingual delivery technology. Its lead high-dose sublingual aspirin product has completed a positive pharmacokinetic clinical study showing faster blood availability and stronger platelet inhibition than standard oral aspirin, with a 505(b)(2) NDA submission targeted for 2026. The company is also advancing sublingual melatonin, vitamin, caffeine and other formulations, including its “Buzz Bomb” caffeine supplement line.
Aspire Biopharma Holdings, Inc. has filed an S-1 to register the resale of up to 159,090,906 shares of common stock issuable upon conversion of its Series A Convertible Preferred Stock. These shares may be sold from time to time by selling shareholders, and the company will not receive proceeds from these resales.
The Preferred Stock supports up to $20,000,000 of financing, with a first tranche of $11,000,000 already funded, partly via debt conversion, and a potential second tranche of up to $10,000,000 tied to this registration’s effectiveness. Conversion is priced off market trading levels with a floor price of $0.264 per share and is limited by a 4.99% beneficial ownership cap, adjustable to 9.99% with notice, to restrict any single investor’s stake.
Aspire is an early-stage biopharmaceutical and supplements company focused on patent-pending sublingual delivery technologies, led by a high-dose sublingual aspirin program that has completed a positive pharmacokinetic trial and is being advanced toward a planned 505(b)(2) NDA submission targeted for late 2026. The company is also commercializing “Buzz Bomb” caffeine supplements and developing additional sublingual products, including melatonin, vitamins, nicotine and other drug candidates, while managing a complex capital structure that includes past convertible notes, an equity line of credit and reverse recapitalization through a SPAC merger.